Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Polycystic ovary syndrome (PCOS) is a common endocrine disease that is frequently observed to be related to increased insulin resistance independent of body weight. The use of insulin-sensitizer compounds, such as metformin, permits great improvement of such metabolic abnormality, restoring ovarian function and gonadal steroid synthesis and reducing insulin resistance. AIM: On this basis we aimed to evaluate a group of non-obese amenorrheic PCOS patients before and after 6 months of metformin administration (500 mg orally twice daily) to better understand upon which basis of clinical and endocrine parameters metformin administration might be chosen as a putative therapeutic tool. METHOD: A group of non-obese PCOS patients (n = 42) was enrolled after informed consent. They underwent an oral glucose tolerance test for insulin, glucose and C-peptide levels and provided blood samples for determination of plasma levels of luteinizing hormone (LH), follicle-stimulating hormone, prolactin, estradiol, androstenedione, 17-hydroxyprogesterone, insulin, cortisol and testosterone levels on two occasions: before and on day 7 of the first menstrual cycle occurring after the 5th month of treatment. RESULTS: Plasma LH, estradiol, insulin and C-peptide were decreased significantly by metformin treatment in the entire group of PCOS patients. When subdividing PCOS patients according to insulin sensitivity (i.e. hyper- and normoinsulinemic subjects), a greater rate of positive endocrine changes was observed in hyperinsulinemic patients and the highest rate was observed in hyperinsulinemic hyperandrogenic subjects. Menstrual cyclicity was recovered in all patients under treatment. CONCLUSIONS: Our data show that metformin modulates ovarian function and greatly affects LH secretion through reduction of the hyperandrogenic condition. The highest rate of endocrine changes was observed in the hyperinsulinemic hyperandrogenic non-obese PCOS patients. Our study demonstrates that metformin administration is more appropriate in hyperinsulinemic hyperandrogenic non-obese PCOS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Franks, S. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509283331307 · Cited by 2,463
Lillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368 · cited 1×
“Among the available compounds, metformin, a water-soluble oral biguanide, enhances insulin sensitivity in liver, where it inhibits hepatic glucose production, and in muscle tissue, where it improves glucose uptake and utilization [8,12], with minimal side-effects such hypoglycemia [13] and with no direct effect on ins…”
BackgroundVelazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865
NESTLER, J. E., POWERS, L. P., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., RITTMASTER, R. S., CLORE, J. N., & BLACKARD, W. G. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-83 · Cited by 815
Nestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743
Dunn, C. J., & Peters, D. H. (1995) · Drugs · doi:10.2165/00003495-199549050-00007 · Cited by 391
Sensitization to Insulin Induces Ovulation in Nonobese Adolescents with Anovulatory Hyperandrogenism
Ibáñez, L., Valls, C., Ferrer, A., Marcos, M. V., Rodriguez-Hierro, F., & de Zegher, F. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7756 · Cited by 162 · cited 1×
“Many studies have demonstrated the efficacy of insulin-sensitizing compounds, such as metformin, in reducing PCOS-associated hyperinsulinemia and in correcting most of the endocrine and metabolic abnormalities found in women with PCOS [1,2,10,12].”
Background
Cited by
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications
Diamanti-Kandarakis, E. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000598 · Cited by 294
“132 Genazzani, A. et al. (2007) Metformin administration is more effective when non- obese”
BackgroundGenazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221
“Indeed, in our study, MYO decreased insulin plasma levels, glucose-to-insulin ratio, HOMA index as well as other hormonal parameters such as LH, LH/FSH, testosterone and PRL, typically elevated in PCOS patients and determined the occurrence of normal menstrual cycles in all patients under study similarly to DCI [14,16…”
BackgroundSelf-citationEffects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
Unfer, V., Carlomagno, G., Dante, G., & Facchinetti, F. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.650660 · Cited by 201
Artini, P. G., Di Berardino, O. M., Papini, F., Genazzani, A. D., Simi, G., Ruggiero, M., & Cela, V. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2012.743020 · Cited by 154
“In the last years, a great body of evidence has demonstrated the important role of altered insulin sensitivity in many, though not all, PCOS patients [3].”
Background
Metadata
- Authors
- Genazzani, A. D., Lanzoni, C., Ricchieri, F., Baraldi, E., Casarosa, E., & Jasonni, V. M.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2007-01
- Volume
- 23
- Issue
- 3
- Pages
- 146-152
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W1983241149
- Cited by
- 62
- References
- 8
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. https://app.cochat.ai/papers/10.1080/09513590701214398
- The paper
- Genazzani, A. D., Lanzoni, C., Ricchieri, F., Baraldi, E., Casarosa, E., & Jasonni, V. M. (2007). Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecological Endocrinology. https://doi.org/10.1080/09513590701214398
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.